Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPN11_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTPN11_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPN11_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTPN11_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTPN11_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
GO:003238618 | Esophagus | ESCC | regulation of intracellular transport | 243/8552 | 337/18723 | 3.20e-23 | 7.25e-21 | 243 |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0051168110 | Esophagus | ESCC | nuclear export | 126/8552 | 154/18723 | 1.88e-20 | 2.65e-18 | 126 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0033157110 | Esophagus | ESCC | regulation of intracellular protein transport | 169/8552 | 229/18723 | 3.31e-18 | 3.23e-16 | 169 |
GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:0046822110 | Esophagus | ESCC | regulation of nucleocytoplasmic transport | 88/8552 | 106/18723 | 1.88e-15 | 1.19e-13 | 88 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:0150115110 | Esophagus | ESCC | cell-substrate junction organization | 77/8552 | 101/18723 | 3.46e-10 | 9.57e-09 | 77 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:000704418 | Esophagus | ESCC | cell-substrate junction assembly | 73/8552 | 95/18723 | 5.27e-10 | 1.35e-08 | 73 |
GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0462512 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0522019 | Oral cavity | OSCC | Chronic myeloid leukemia | 56/3704 | 76/8465 | 1.04e-07 | 7.43e-07 | 3.78e-07 | 56 |
hsa0521117 | Oral cavity | OSCC | Renal cell carcinoma | 51/3704 | 69/8465 | 3.30e-07 | 2.05e-06 | 1.04e-06 | 51 |
hsa0512017 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa052351 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa04670113 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0520845 | Oral cavity | EOLP | Chemical carcinogenesis - reactive oxygen species | 66/1218 | 223/8465 | 2.50e-09 | 5.76e-08 | 3.40e-08 | 66 |
hsa0462541 | Oral cavity | EOLP | C-type lectin receptor signaling pathway | 38/1218 | 104/8465 | 1.39e-08 | 1.83e-07 | 1.08e-07 | 38 |
hsa052352 | Oral cavity | EOLP | PD-L1 expression and PD-1 checkpoint pathway in cancer | 32/1218 | 89/8465 | 2.96e-07 | 3.18e-06 | 1.88e-06 | 32 |
hsa04670210 | Oral cavity | EOLP | Leukocyte transendothelial migration | 37/1218 | 114/8465 | 7.00e-07 | 6.85e-06 | 4.04e-06 | 37 |
hsa0513045 | Oral cavity | EOLP | Pathogenic Escherichia coli infection | 54/1218 | 197/8465 | 1.10e-06 | 9.96e-06 | 5.87e-06 | 54 |
hsa0521141 | Oral cavity | EOLP | Renal cell carcinoma | 25/1218 | 69/8465 | 4.96e-06 | 3.27e-05 | 1.93e-05 | 25 |
hsa0472242 | Oral cavity | EOLP | Neurotrophin signaling pathway | 36/1218 | 119/8465 | 6.23e-06 | 3.87e-05 | 2.28e-05 | 36 |
hsa0520543 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa04650 | Oral cavity | EOLP | Natural killer cell mediated cytotoxicity | 38/1218 | 132/8465 | 1.26e-05 | 7.01e-05 | 4.13e-05 | 38 |
hsa0522041 | Oral cavity | EOLP | Chronic myeloid leukemia | 24/1218 | 76/8465 | 1.01e-04 | 4.48e-04 | 2.64e-04 | 24 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | II-B08 | | 20170098 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | U0126 | | 17942397 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | 4-HYDRAZINYLBENZENESULFONIC ACID | CHEMBL510966 | 19007293 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | cryptotanshinone | CRYPTOTANSHINONE | 23957426 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | PLX4720 | PLX-4720 | 26351322 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | MESO-2,3-DIMERCAPTOSUCCINIC ACID | CHEMBL28721 | |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | OLTIPRAZ | OLTIPRAZ | 20655236 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | Refametinib | REFAMETINIB | |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | N/A | | 19047918,21901340 |
5781 | PTPN11 | DRUGGABLE GENOME, KINASE, PROTEIN PHOSPHATASE, ENZYME, CLINICALLY ACTIONABLE | | TNO155 | | |